Long-term (5–6 years) belimumab treatment is safe and might retard the accrual of organ damage in patients with systemic lupus erythematosus (SLE), according to a newly published report. The analysis, which pooled data from 998 patients who completed BLISS-52 and BLISS-76 and were enrolled in open-label continuation studies, reveals no new safety concerns and finds consistently low rates of damage accrual — SLICC (SLE International Collaborating Clinics)/ACR Damage Index (SDI) accrual +0.2 — in all patients receiving belimumab plus standard care, including those with organ damage at baseline (this high-risk group comprised 411 patients, 235 with SDI = 1 and 176 with SDI ≥2). All patients initially received the same belimumab dose as in the parent studies (either 1 mg/kg or 10 mg/kg every 4 weeks), but those receiving the low dose were switched to 10 mg/kg following a protocol amendment.